H.C. Wainwright analyst Mitchell Kapoor initiated coverage of Halozyme Therapeutics with a Buy rating and $61 price target. Halozyme is a biopharmaceutical technology platform company focused on improving patient experiences and outcomes, the analyst tells investors in a research note. The firm says the company is improving the way that drugs are administered and delivered.
Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
See Insiders’ Hot Stocks on TipRanks >>
Read More on HALO: